EVO

#6991
Evotec SE American Depositary Shares
3.4000
+0.89%
Secteur:
Base:
Devise de Profit:
Range quotidien
3.4000
3.4000
Range Annuel
2.8600
4.2700
Changement quotidien
+0.89%
Changement Mensuel
-9.33%
Evolution sur 6 mois
-20.37%
Changement Annuel
-20.37%
Clôture Précédente
3.3700
Open
3.4000
Bid
Ask
Low
3.4000
High
3.4000
Volume
7
Open full chart

Financials

Overview Relevé Statistics Dividends
Quarterly Annual
  • Market Capitalization N/A
  • Employee 4 766
  • Founded 1993
  • CEO N/A
  • Website www.evotec.com
  • Headquarter Germany
  • FIGI BBG000LFTJ81
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
—
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Evotec SE - American Depositary Shares each representing 1/2 of

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology.

Nouvelles